Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPRX-106 in mild to moderate ulcerative colitis
NCT02768974Phase 2Unknown
- Sponsor
- Protalix BioTherapeutics
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OPRX-106 in ulcerative colitis (UC) (2 arms), sponsored by Protalix BioTherapeutics. Primary endpoint: Adverse events following daily administration of OPRX 106 at 70 days. Status: unknown.
02
Drugs
OPRX-106
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02768974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02768974.